Serum sST2 levels and associated factors in patients with heart failure with reduced ejection fraction following myocardial infarction
Main Article Content
Abstract
This study aimed to investigate serum soluble ST2 concentrations and associated factors in patients with chronic heart failure with reduced ejection fraction following myocardial infarction. A cross sectional analytic study was conducted in 77 patients. The median age was 71.0 years, and 53.2% were male. Most patients had hypertension (93.5%), one third had diabetes mellitus (33.8%), and 15.6% had dyslipidemia. Serum sST2 concentrations increased progressively across New York Heart Association functional classes from II to IV with statistical significance (p = 0.005. Multivariable linear regression analysis identified atrial fibrillation and New York Heart Association class III to IV as independent factors associated with serum sST2 concentrations p = 0.028 and p = 0.005, respectively. In conclusion, the median serum sST2 concentration in patients with heart failure with reduced ejection fraction after myocardial infarction was 22.3 ng/mL. Atrial fibrillation and heart failure severity as assessed by the New York Heart Association classification were independently associated with serum sST2 concentrations.
Article Details
Keywords
sST2, serum concentration, heart failure with reduced ejection fraction, myocardial infarction, associated factors
References
2. Crnko S, Printezi MI, Jansen TPJ, et al. Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients. ESC heart failure. 2020;7(3):1224-1233. doi:10.1002/ehf2.12673
3. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. Journal of the American College of Cardiology. 2010;55(3):243-50. doi:10.1016/j.jacc.2009.08.047
4. Grande D, Leone M, Rizzo C, et al. A Multiparametric Approach Based on NT-proBNP, ST2, and Galectin3 for Stratifying One Year Prognosis of Chronic Heart Failure Outpatients. Journal of cardiovascular development and disease. 2017;4(3)doi:10.3390/jcdd4030009
5. Lotierzo M, Dupuy AM, Kalmanovich E, et al. sST2 as a value-added biomarker in heart failure. Clinica chimica acta; international journal of clinical chemistry. 2020;501:120-130. doi:10.1016/j.cca.2019.10.029
6. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195
7. Chen Y, Guan J, Qi C, et al. Association of point-of-care testing for sST2 with clinical outcomes in patients hospitalized with heart failure. ESC heart failure. 2024;11(5):2857-2868. doi:10.1002/ehf2.14860
8. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/cir.0000000000001063
9. Bahuleyan CG, Alummoottil GK, Abdullakutty J, et al. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - A multicenter study. Indian heart journal. 2018;70 Suppl 1(Suppl 1):S79-s84. doi:10.1016/j.ihj.2017.09.010
10. Dudek M, Kałużna-Oleksy M, Migaj J, et al. sST2 and Heart Failure-Clinical Utility and Prognosis. Journal of clinical medicine. 2023;12(9)doi:10.3390/jcm12093136
11. Hoàng Anh Tiến, Trần Thị Thanh Trúc, Nhân VT. Nghiên cứu sự kết hợp SST2 và bnp huyết thanh trong tiên lượng suy tim và tử vong trong 30 ngày ở bệnh nhân nhồi máu cơ tim cấp ST chênh lên. Tạp chí Y Dược học. 2016;32:61. doi:10.34071/jmp.2016.2.9
12. Dương Hồng Niên, Nguyễn Xuân Tiện, Vũ Xuân Nghĩa, và cs. Nghiên cứu mối liên quan giữa biến đổi nồng độ sST2 huyết thanh và một số đặc điểm lâm sàng ở bệnh nhân suy tim mạn tính sau một đợt điều trị. Tạp chí Y học Việt Nam. 2023;529(1B):166 - 170. doi:10.51298/vmj.v529i1B.6367
13. Yan X, Guo Y, Li L, et al. The sST2 level is an independent influencing factor associated with atrial fibrillation in heart failure patients: a case-control study. Journal of thoracic disease. 2022;14(5):1578-1587. doi:10.21037/jtd-22-470
14. Vallejo-Vaz AJ. Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2. European cardiology. 2015;10(1):37-41. doi:10.15420/ecr.2015.10.01.37
15. Wang Z, Pan X, Xu H, et al. Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure. Frontiers in cardiovascular medicine. 2022;9:812654. doi:10.3389/fcvm.2022.812654